Cellceutix to deliver Poster on Novel Anti
BEVERLY, MA (Marketwired) 05/28/13
Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused entirely on discovering small molecule drugs to handle unmet medical ailments, including drugresistant cancers and autoimmune diseases, announces today that it's going to be presenting a poster in the company's p53activating drug, Kevetrin, in the 2013 American Society of Clinical Oncology ("ASCO") Annual Meeting being stored in Chicago, Illinois from May 31 through June 4, 2013.
An abstract within the poster, titled, "A phase I, doseescalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors," is now ニューバランス 別注 positioned on the ASCO website at DanaFarber Cancer Institute and Beth Israel Deaconess Emergency room," said Dr. are aware that the oncology community and shareholders enjoy a strong interest regarding schedule, maximum tolerated dose and potential efficacy of Kevetrin, given its uniqueness and potential. The laboratory informed us that additional samples were vital for analysis of Kevetrin's affect on biomarker p21, an earlystage indicator of efficacy. Those samples happen to be given by a healthcare facility with additional to generally be delivered when the trial progresses. We're hopeful that data will undoubtedly be easily obtainable in time for ASCO. We anticipate the Evidence Concept trial to begin with in August and take 8 weeks being completed. In the recent market enthusiasm towards Celgene's research of Apremilast, we are attempting to commence our clinical research of Prurisol."
Being cutting edge class of chemistry in medicine, http://www.plastindia.org/images/hom...menu.asp?q=579 Kevetrin" has significant chance to often be a major breakthrough inside the treating of solid tumors. Mechanism of action studies showed Kevetrin's unique power to affect both wild and mutant different kinds of p53 (also known as the "Guardian Angel Gene" also know as the "Guardian Angel from the Human Genome") which Kevetrin strongly induced apoptosis (cell death), seen as a activation of Caspase 3 and cleavage of PARP. Activation of p53 also induced apoptosis by creating the expression of p53 target gene PUMA. p53 can be a tumor suppressor that http://unipaints.com/crm/index.asp?q=1000 acts to limit proliferation by inducing cell cycle checkpoints, apoptosis, or cellular senescence.
In many than Fifty % among all human carcinomas, p53 is fixed inside the antitumor activities by mutations inside the protein itself. Currently, there is more than 10 million those with tumors which contain inactivated p53, while the identical number have tumors that the p53 pathway is partially abrogated by inactivation of other signaling components. It really has left cancer researchers using the grand challenge of interested in therapies that would restore the protein's protective function, which Kevetrin is definetly doing the majority of the time.
More info on the medical study, titled "A Phase 1, OpenLabel, DoseEscalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors," exists at:
Headquartered in Beverly, Massachusetts, Cellceutix can be described as publicly operated company below the symbol It is deemed an emerging biopharmaceutical company focused on the development of its pipeline of compounds targeting areas of unmet medical need. Our flagship compound, Kevetrin is really an anticancer drug which contains demonstrated the flexibility in preclinical studies to alter the p53 pathway and attack cancers that contain proven from today's cancer therapies (drugresistant cancers). Cellceutix also owns the rights to seven other drug compounds, including KM133, that is in development for psoriasis, and KM391 to your cure for the core the signs of autism. Addiitional information can be obtained on the Cellceutix internet site at
To the extent that statements from this blog post typically are not strictly historical, including statements about revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the achievements of companyname's mailing address development, events conditioned on stockholder or other approval, or of future events, such statements are forwardlooking, and are made pursuant in the safe harbor provisions of one's Private Securities Litigation Reform Act of 1995. The forwardlooking statements from this release are cause to undergo certain risks and uncertainties which might cause actual leads to differ materially with the statements made. Filing.